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Abstract
Background: There is heterogeneity among obese individuals, as some appear to have healthier metabolic profiles
and decreased health risks. These individuals are defined as metabolically healthy obese (MHO), whilst those with
unhealthy metabolic profiles are defined as metabolically unhealthy obese (MUO). To date, most research on MHO
has been cross-sectional or focused on disease prognosis. However, longitudinal studies are required to provide
greater insight into the life course factors that contribute to the development of MHO. This study aims to
systematically review longitudinal studies investigating the association between life course exposures and
future MHO status.
Methods: Electronic databases (MEDLINE, SCOPUS, and Web of Science) will be searched using a trialled
search strategy. Studies will be included following a double-screening process according to inclusion criteria
to assess eligibility. Studies eligible for inclusion will include those that have a longitudinal observational
design where a life course exposure occurred or was measured at least 1 year before the outcome, investigate a
human study population, are published in English after 1956, and investigate the association between ≥ 1 life
course exposure and ≥ 1 outcome that reflects a measure of cardiometabolic resilience to obesity. Accepted life
course exposures will include body size, body composition, pubertal development, smoking, diet, physical activity,
sedentary behaviour, and psychosocial stress. The primary measure of cardiometabolic resilience to obesity will
be MHO as an outcome (at follow-up). Studies investigating the development of cardiometabolic risk factors in
an obese group without specifying MHO will also be accepted, such as the development of the metabolic
syndrome (MetS) in an obese group. Key results of included studies will be tabulated, and a narrative synthesis
will be conducted.
Discussion: This will be the first systematic review to summarise the literature on the life course correlates of
MHO. Importantly, it may highlight which modifiable lifestyle factors could be targeted to delay the onset of
cardiometabolic complications among the obese.
Systematic review registration: PROSPERO CRD42017057992
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Background
Obesity, which is most commonly defined as a body mass
index (BMI) ≥ 30 kg/m2, is a public health problem in
both developed and developing countries, with the global
age-standardised obesity prevalence estimated to be 25.7%
[1]. Obesity and its associated disease outcomes such as
type 2 diabetes mellitus (T2DM), cancer, and cardiovascu-
lar disease (CVD) pose an individual and economic bur-
den worldwide. It is estimated that by 2030, the costs due
to preventable diseases associated with obesity will cost
the United Kingdom (UK) £26 billion and the Unites
States of America (USA) $66 billion annually [2].
However, obese individuals do not form a single
homogenous group. Research has demonstrated that a
subset of obese individuals has healthier metabolic pro-
files and decreased health risks compared to other obese
participants [3]. The concept of metabolically healthy
obesity (MHO) and metabolically unhealthy obesity
(MUO) has thus been proposed. Metabolically healthy
obesity is a condition characterised by obesity in the ab-
sence of metabolic abnormalities (e.g. high blood pres-
sure, high blood glucose, adverse lipid profile). On the
other hand, metabolically unhealthy obesity (MUO) is
characterised by obesity accompanied by metabolic ab-
normalities. The estimated prevalence of the MHO
phenotype varies due to inconsistencies in the criteria
used to define MHO [3], but it has been estimated to be
in the range of 10–47.7% [4–7].
Much research has looked at the disease prognosis as-
sociated with MHO and MUO. It has been proposed
that MHO is not a stable condition, rather a transient
state before the development of MUO [8]. Studies have
demonstrated high rates of transitioning from MHO to
MUO, with transitioning rates increasing with longer
follow-up periods [8–10]. For example, studies have
found over 1 year of follow-up 21.4% of MHO individ-
ual’s transition to MUO [9], over eight and a half years
of follow-up 44.% of MHO transition to MUO [8], and
over 10 years of follow-up 64.7% transition [10].
Further, it is unlikely that MHO is a completely benign
condition, rather a condition where the cardiometabolic
health risks are intermediate between MUO and meta-
bolically healthy normal weight (MHNW). For example,
a meta-analysis of prospective cohort studies found
MHO individuals to have approximately four times in-
creased risk (relative risk (RR) = 4.03, 95% confidence
interval (CI) 2.66–6.09) and MUO approximately nine
times increased risk of developing T2DM (RR = 8.93,
95% CI 6.86–11.62), compared to MHNW [11]. Simi-
larly, another meta-analysis found the same pattern for
relative risk of developing CVD [12].
Although research demonstrates that MHO is not be-
nign and may be an intermediate state before the develop-
ment of MUO, understanding which life course factors
are related to MHO is still important [13, 14]. Under-
standing the life course factors which are related to MHO
may inform us of potentially modifiable lifestyle factors
which could be the focus of interventions to prevent or
delay the development of cardiometabolic disease, even in
the presence of obesity.
To date research which has investigated why differ-
ences exist between the metabolic health of obese indi-
viduals has been largely cross-sectional [15–20]. For
example, higher physical activity [15–18], lower seden-
tary time [17], and smoking [18] have been found to be
cross-sectionally associated with the MHO phenotype.
In the literature, there appears to be a less longitudinal
analysis of factors associated with MHO. Longitudinal
analysis of factors associated with MHO would better
infer the direction of possible associations and provide a
superior estimate of causality, compared to current
cross-sectional analyses of such associations. Further,
longitudinal analyses are required to elucidate factors
across the life course which may predict MHO and
could thus be the target of prevention programmes.
To date, no systematic review has summarised the exist-
ing longitudinal studies investigating the correlates of
MHO. The aim of this study will be to systematically re-
view the literature on the life course correlates of MHO,
focusing on body size, body composition, pubertal devel-
opment, lifestyle behaviours, and psychosocial stress.
Methods
Registration
This study protocol is registered with the PROSPERO
database (registration number: CRD42017057992).
Search methods
Three medical databases will be searched; these include
MEDLINE, Scopus, and Web of Science. Studies will be
searched for using the EBSCO interface for the MEDLINE
database, the Elsevier interface for the Scopus database,
and the Thomson Reuters interface for the Web of Sci-
ence database. The search for eligible studies will be car-
ried out in a systematic manner, using synonym free-text
words to identify eligible articles until the date of the last
search. Truncation commands, Boolean logic, and prox-
imity operators will be used when carrying out the
searches and adapted in line with the interface used, see
Table 1 for search tools and techniques to be used.
The search strategy has been developed using previous
literature which has highlighted relevant key themes or
strong theoretical rationale for the inclusion of certain
themes. Search terms have been discussed between au-
thors, and piloted in a variation of trialled search strat-
egies, to enhance the efficacy of the final search, see
Additional files 1, 2, and 3 for the search strategies used.
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Search results from the different interfaces will be
exported into RefWorks and merged. Following this,
RefWorks will be used to search for duplicates, using a
combination of automatic and manual processes. Firstly,
the ‘Search for duplicates’ command will be used, and
identified duplicates will be removed. Secondly, the
remaining records will be manually screened for possible
remaining duplicates, and any identified duplicate re-
cords will be eliminated.
Eligibility criteria
There will be two phases to the selection of studies to be
included in the review. In each phase articles will be
screened according to the following eligibility cri-
teria outlined in Table 2. Screening of studies will be a
semi-automated process using distillerSR® software.
Exposure(s)
Life course exposures will include body size (e.g. body
size trajectories, BMI, waist-to-hip ratio (WHR), height),
body composition (e.g. muscle mass, fat mass, visceral
fat), pubertal development (e.g. age of onset of puberty,
tanner stages, menarche, genetic variants for puberty),
lifestyle behaviours (e.g. smoking, physical activity, sed-
entary behaviour, diet), and psychosocial stress measures
(e.g. adversity, maltreatment, anxiety, depression, socio-
economic status, social occupational class, income, edu-
cation and measures of the stress response, e.g. diurnal
cortisol rhythms). To be included, exposures can be
measured at any point in the participants’ lifetime, but
this must be before the outcome of cardiometabolic re-
silience to obesity has been measured. The exposure
measurements can be self-reported or measured directly
by researchers or medical staff.
Outcome(s)
Studies will be included if they have measured cardio-
metabolic resilience to obesity as an outcome. Cardio-
metabolic resilience in the present study is defined as an
obese individual’s resilience to the typical cardiometa-
bolic complications that accompany carrying excess
weight, for example, the development of unfavourable
metabolic profiles, such as elevated blood pressure, ab-
normal lipid profiles, impaired glucose metabolism, and
systemic inflammation [21].
Table 1 Tools and techniques that will be used in the online database search
Tool/technique Description Example
Capturing phrases (phrase) used in MEDLINE database searching and
“phrase” used in Scopus and Web of Science databases.
(body size trajector*)
“body size trajector*”
Boolean logic operators ‘AND’ to combine searches, so databases search for
the combination instead of singular search fields.
Search field 1 AND search field 2 AND search field 3
‘OR’ will be used to instruct the database to only
retrieve results with at least one of the search terms.
Smok* OR diet* OR alcohol* OR ‘physical activit*’
OR exercis* OR fit* OR psychosocial OR stress*
Proximity operators NEAR/3 will be used when using Web of Science, W/3
when using Scopus, and N3 when using MEDLINE.
These proximity operators instruct the database to only
retrieve 2 or more words if they are within 3 words of
each other.
Metabolic* NEAR/3 health* NEAR/3 obes*
Metabolic* W/3 health* W/3 obes*
Metabolic* N/3 health N/3 obes*
Truncation commands ‘root word*’ the asterisks is inputted where the root
word naturally finishes, and this instructs the search
engine to capture all possible variations of the root
word, by searching all the possible word endings.
Exercis* will capture: exercise, excercising, exercised
Restrictions Dependent upon the search engine used, filters
can be used to restrict searches.
MEDLINE via EBSCO:
Date of publication 1960-2017
Source Type: Academic journals
Scopus via Elsevier
English Language
Date of publication 1960-2017
Publication type: articles
Web Of Science via Thomas Reuters
English Language
Date of publication 1946-2017
Publication type: articles
Table 2 Eligibility criteria
Eligibility question Response
• 1) Study population: Is a human study population
being investigated?
Yes, No, or
Not Clear
• 2) Association: Is the study testing the association
between ≥ 1 life course exposure (i.e. body size,
body composition, pubertal development, lifestyle
behaviour, or psychosocial stress) and ≥ 1 measure
of cardiometabolic resilience to obesity as an outcome?
Yes, No, or
Not Clear
• 3) Study design: Is it a longitudinal observational
design where the life course exposure occurred or
was measured ≥ 1 year before the outcome?
Yes, No, or
Not Clear
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The primary measure of cardiometabolic resilience to
obesity will be MHO. To date, there is no universal con-
sensus of a standard definition to diagnose MHO [22].
Some studies use obesity accompanied by the presence or
absence of metabolic syndrome (MetS) to diagnose MUO
or MHO, whilst some studies use the presence or absence
of selected cardiometabolic risk factors, and other studies
additionally incorporate the presence or absence of inflam-
matory markers into their definitions [22]. Therefore, the
present study will accept any method of diagnosing MHO,
due to the lack of universal consensus on a definition.
Other terms used to describe MHO or MUO such as car-
diometabolic/metabolic health/unhealthy obese/obesity,
cardiometabolic/metabolic abnormal/normal obese/obes-
ity, and cardiometabolic/metabolic benign/at-risk obesity
will be accepted as a measure of MHO.
In addition, there are studies where the development
of cardiometabolic risk factors is investigated in obese
individuals, but the metabolic status is not specifically
defined or implied as being ‘healthy’ or ‘unhealthy’; these
studies will also be included, for example, studies inves-
tigating the presence or absence of MetS in an obese
group, where MHO/MUO is not defined specifically.
Selection of studies
There will be two phases to the selection of studies to be
included in the review. In each phase, articles will be
screened according to the following eligibility criteria:
Phase 1
Following retrieval of articles found via database search-
ing, title and abstracts of these articles will be screened
by a primary reviewer (ER) according to the eligibility
criteria. Articles with responses ‘yes’ or ‘not clear’ to all
three eligibility criteria checkpoints will pass to phase 2,
if not, they will be excluded.
Phase 2
The full texts for potentially eligible articles found via
database searching will be obtained and screened by the
primary reviewer (ER) against eligibility criteria. This will
be carried out. If responses to all four eligibility criteria
checkpoints are ‘yes’, the study will be included in the
systematic review. If any of the responses are ‘not clear’,
the study in question will be discussed with the senior
author and a decision whether to include or exclude the
study will be made. If any of the responses is ‘no’, the
study will be excluded and the reason(s) noted.
Following this, a random 10% of the full texts screened
in phase 2 will be double-screened by a secondary re-
viewer (WJ) and compared against the same 10%
screened by the primary reviewer. If any discrepancies
occur between the two reviewers in the decision to
include or exclude articles in the 10% of randomly se-
lected studies, they will be resolved by the team and
recorded.
Data extraction and management
Data to be extracted will include data on the citation,
study design, participant, exposure(s), outcome(s), and
statistical analyses. This data will be extracted by the pri-
mary reviewer and inputted into data extraction forms
(see Additional file 4). If any doubt arises during the ex-
traction of this information or what to extract, it will be
discussed with the secondary reviewer. If any uncertainty
arises, it will be recorded.
Quality assessment
The Newcastle-Ottawa Quality Assessment Scale [23]
for cohort studies will be used to assess the quality of in-
cluded studies and modified where necessary, to suit the
nature of the studies included in the review. Modifica-
tions will be made to ensure that the three most funda-
mental domains are being assessed, which include
appropriate selection of participants, measurement of
variables, and control of confounding [24], see
Additional file 5 for the modified scale that will be used.
Quality assessment will be a manual process. Data will
be extracted and inputted into quality assessment forms
and a score calculated (see Additional file 6); these
scores will then be reported. Three main domains will
be assessed: selection, comparability, and outcome. Se-
lection domain assesses the representativeness of the co-
hort, whether the sample used in the analysis is
representative of the initial cohort, ascertainment of bio-
logical exposures, and whether there is a demonstration
of presence or absence of the outcome at the start of the
study. Comparability assesses whether studies have con-
trolled for confounders in their main analyses. Outcome
assesses ascertainment of the outcome, whether the
follow-up period was long enough for outcomes to occur
and whether the follow-up of cohorts was adequate.
Quality assessment will be carried out primarily by re-
viewer ER, and secondary reviewer WJ will assess 10% of
the included studies. Any discrepancies between quality
assessment scored by the two reviewers will be noted,
discussed, and resolved.
Strategy for synthesis
Key information on characteristics, results, and quality
scores of included studies will be tabulated (see
Additional files 4 and 6). Following this, a narrative syn-
thesis will be conducted. The review will not include a
meta-analysis because we are not summarising literature
on a single or a few simple associations. Our search
strategy allows for multiple exposures, outcomes, and
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study designs, thereby making an a priori decision to
conduct a meta-analysis of results unjustified.
Firstly, in the narrative review, the number of studies
to be included in the synthesis will be reported, and
characteristics of studies will be described, including the
location and study population.
Secondly, the narrative synthesis will report and dis-
cuss the methods used to define primary (MHO) and
secondary outcomes (MetS in an obese group), and the
quality of the methods used will be critiqued.
Finally, associations of life course factors and primary
(MHO) and secondary outcomes (MetS in an obese
group) will be explored. The findings of studies will be
grouped according to exposure type: body size (e.g. body
size trajectories, BMI, WHR, height), body composition
(e.g. muscle mass, fat mass, visceral fat), pubertal devel-
opment (e.g. age of onset of puberty, tanner stages, me-
narche, genetic variants for puberty), lifestyle behaviours
(smoking, physical activity, sedentary behaviour, diet),
and psychosocial stress exposures (e.g. adversity, mal-
treatment, anxiety, depression, socioeconomic status, so-
cial occupational class, income, education, and measures
of the stress response). Within this, similarities and dif-
ferences of findings will be reported, the strength of
findings will be reflected upon, and between-study het-
erogeneity will be evaluated.
Amendments to protocol
Any substantial changes to the protocol will be regis-
tered with PROSPERO and will be documented in the
final publication of the systematic review.
Reporting
This protocol is being reported according to the ‘Preferred
Reporting Items for Systematic Reviews and Meta-analysis
Protocols (PRISMA-P) 2015 statement’ [25], see Add-
itional file 7 for the PRISMA-P 2015 checklist. The sys-
tematic review and findings will be reported according to
the ‘Preferred Reporting Items for Systematic Reviews and
Meta-Analyses: the PRISMA statement (2009)’ [26].
Dissemination
The review will be published in an international, peer-
reviewed journal. Further, results will be presented to the
research community and wider public, via a number of aca-
demic and non-academic outlets. For example, results will
be presented at relevant academic conferences, and results
will be summarised and shared via social media channels.
Discussion
This systematic review will be the first to summarise the
literature on the life course factors associated with MHO.
The relationship between different exposures across the
lifetime and MHO or MUO outcome and features of
between-study heterogeneity will be explored.
This information will be important in understanding
what we currently know on the subject of cardiometa-
bolic resilience to obesity and identifying gaps for future
research. In particular, results of the study offer the po-
tential to highlight which modifiable lifestyle factors
could be targeted in prevention, intervention, or treat-
ment programmes to delay the onset of cardiometabolic
complications among the obese. Helping to improve the
health outcomes of the obese is of particular significance
considering the high rates of obesity globally [1], and the
financial burden placed upon countries healthcare sys-
tems, in part due to the cardiometabolic complications
associated with overweight and obesity [2].
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